Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

A Phase II Study of Low Dose Melphalan with Thiotepa and Fludarabine As Preparative Regimen for Alternative Donor Transplantation

Nikki Agarwal, Pingfu Fu, Michael Daunov, Brenda W Cooper, Ben K. Tomlinson, Rebecca B. Klisovic, Marcos de Lima, Folashade Otegbeye, Changchun Deng, Yeritza Hernandez-Collazo, Jignesh Dalal, James Martin, Seunghee Margevicius, James J. Ignatz-Hoover, Ok-Kyong Chaekal, Molly Megan Gallogly, Koen van Besien, Leland Metheny

Blood (2024) 144 (Supplement 1): 2131.

https://doi.org/10.1182/blood-2024-210550

Published: 2024

Journal Articles

Autoimmune Outcomes in Patients with Concurrent Autoimmune Disease Receiving CD19 CAR T-Cell Therapy for Lymphoma

Jennifer J. Huang, Namrata Singh, Mazyar Shadman, Ryan S. Basom, Andrea Kalus, Andrew J Portuguese, Emily C Liang, Natalie Wuliji, Alexandre V. Vinaud Hirayama, Aude G Chapuis, Folashade Otegbeye, Filippo Milano, Ryan D. Cassaday, Ajay K. Gopal, Brian G. Till, Edus H. Warren, Jordan Gauthier, Lawrence Fong, David G. Maloney

Blood (2024) 144 (Supplement 1): 7132.

https://doi.org/10.1182/blood-2024-201809

Published: 2024

Journal Articles

Phase 2 Study of CD19 CAR T Cells with a Fully Human Binder for Large B-Cell Lymphoma in Relapse or Progression after a Murine Binder-Bearing CD19 CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 6860.

https://doi.org/10.1182/blood-2023-181273

Published: 2023

Journal Articles

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 2143.

https://doi.org/10.1182/blood-2023-174106

Published: 2023

Journal Articles

Day +3/Day 0 Ferritin Ratio: A Simple Point-of-Care Index Predictive of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome after CD19 CAR T-Cell Therapy

Blood (2023) 142 (Supplement 1): 3495.

https://doi.org/10.1182/blood-2023-182597

Published: 2023

Journal Articles

Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting

Andrew J Portuguese, Aya Albittar, Emily C Liang, Jennifer J. Huang, Alexandre V Hirayama, Erik L Kimble, Lorenzo Iovino, Christina Poh, Ajay K Gopal, Mazyar Shadman, Brian G Till, Hans-Peter Kiem, Filippo Milano, Aude G Chapuis, Folashade Otegbeye, Ryan D Cassaday, David G Maloney, Jordan Gauthier

Blood (2023) 142 (Supplement 1): 2131.

https://doi.org/10.1182/blood-2023-172978

Published: 2023

Journal Articles

Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim Analysis

Blood (2023) 142 (Supplement 1): 6848.

https://doi.org/10.1182/blood-2023-172695

Published: 2023

Journal Articles

Multicenter Phase I Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

Leland Metheny, Ronald M. Sobecks, Christina Cho, Jiasheng Wang, Lisa Ciarrone, Paolo F. Caimi, Folashade Otegbeye, Brenda W. Cooper, Molly Gallogly, Ehsan Malek, Aaron T. Gerds, Betty K. Hamilton, Sergio A Giralt, Miguel-Angel Perales, Marcos J.G. de Lima

Blood (2022) 140 (Supplement 1): 1887–1889.

https://doi.org/10.1182/blood-2022-169935

Published: 2022

Journal Articles

Circulating Tumor DNA Correlation with Lymphoma Response and Survival Outcomes at Multiple Time Points of Anti - CD19 CAR T Cell Therapy

Paolo F Caimi, Martina Di Trani, Armin Ghobadi, Jane Reese, Benjamin Tomlinson, Folashade Otegbeye, Kirsten M Boughan, Molly Gallogly, Leland Metheny, Brenda W. Cooper, Boro Dropulic, Marcos J.G. de Lima, Carmelo Carlo-Stella

Blood (2022) 140 (Supplement 1): 7457–7459.

https://doi.org/10.1182/blood-2022-170629

Published: 2022

Journal Articles

Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain

Blood (2021) 138 (Supplement 1): 3833.

https://doi.org/10.1182/blood-2021-151155

Published: 2021

Journal Articles

Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia

Leland Metheny, III, Ronald M. Sobecks, Christina Cho, Paolo F. Caimi, Navneet S. Majhail, Folashade Otegbeye, Kirsten M Boughan, Brenda W. Cooper, Erin Galloway, Molly Gallogly, Ehsan Malek, Benjamin Tomlinson, Aaron T. Gerds, Betty K. Hamilton, Matt Kalaycio, Sergio A Giralt, Marcos J.G. de Lima

Blood (2021) 138 (Supplement 1): 2899.

https://doi.org/10.1182/blood-2021-153041

Published: 2021

Journal Articles

CAR-T Therapy for Lymphoma with Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome without Excessive Neurologic Toxicity

Paolo F Caimi, MD, Ashish Sharma, Patricio Rojas, MD, Seema Patel, PharmD, Jane Reese, Folashade Otegbeye, MBBChir,MPH, Andrew Worden, Michael Kadan, Michael Maschan, MD PhD, Rimas J Orentas, PhD, Boro Dropulic, PhDMBA, Rafick Sekaly, Marcos de Lima, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-143114

Published: 2020

Journal Articles

Final Results of a Dual-Institution Phase I Clinical Trial of Targeted Marrow Irradiation (TMI) Intensification of Reduced-Intensity Fludarabine/Busulfan (Flu/Bu) Conditioning for Allogeneic Hematopoietic Cell Transplantation for Medically Frail Patients with High-Risk Hematological Malignancies

Naveed Ali, MD, Ana Carolina Pires de Rezende, MD, Folashade Otegbeye, MBBChir,MPH, Mariana Nassif Kerbauy, MD, Brenda W. Cooper, MD, David Mansur, MD, Gisele Pereira, PhD, Roberto Sakuraba, MD, Benjamin K. Tomlinson, MD, Kirsten M Boughan, DO, Cinthya Correa Silva, MD, Leland Metheny, III, MD, Andreza Feitosa Ribeiro, MD, Molly M Gallogly, MDPhD, Ehsan Malek, MD, EDuardo Weltman, MD, Marcos de Lima, MD, Nelson Hamerschlak, MD PhD, Paolo F Caimi, MD

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-142197

Published: 2020

Journal Articles

Risk of Secondary Malignancy in CLL Patients Treated with Novel Targeted Agents

Anna Eversman, Shufen Cao, Kirsten M Boughan, DO, Molly M Gallogly, MDPhD, Ehsan Malek, MD, Leland Metheny, III, MD, Timothy E. O'Brien, MD, Folashade Otegbeye, MBBChir,MPH, Brenda W. Cooper, MD, Pingfu Fu, Marcos de Lima, MD, Paolo F Caimi, MD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-140042

Published: 2020

Journal Articles

15-PGDH Inhibition Mitigates Aplastic Anemia Severity

Julianne N. P. Smith, PhD, Folashade Otegbeye, MBBChir,MPH, Alvin Jogasuria, Sanford Markowitz, MD PhD, Amar Desai, PhD

Blood (2019) 134 (Supplement_1): 1220.

https://doi.org/10.1182/blood-2019-131353

Published: 2019

Journal Articles

Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas

Blood (2019) 134 (Supplement_1): 4074.

https://doi.org/10.1182/blood-2019-131300

Published: 2019

Journal Articles

Filgrastim Administered after Early Assessment Bone Marrow Biopsy during 7+3 Induction Therapy for Acute Myeloid Leukemia Reduces Length of Hospital Stay

Jiasheng Wang, MD, Kirsten M Boughan, DO, Paolo F Caimi, MD, Brenda Cooper, MD, Marcos de Lima, MD, Molly M Gallogly, MD PhD, Ehsan Malek, MD, Leland Metheny, III, MD, Folashade Otegbeye, MBBChir,MPH, Shufen Cao, Pingfu Fu, PhD, Benjamin Tomlinson, MD

Blood (2019) 134 (Supplement_1): 2607.

https://doi.org/10.1182/blood-2019-131293

Published: 2019

Journal Articles

Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia

Leland Metheny, III, MD, Ronald Sobecks, MD, Benjamin K. Tomlinson, MD, Folashade Otegbeye, MBBChir,MPH, Brenda Cooper, MD, Navneet S. Majhail, MD MS, Paolo Caimi, MD, Kirsten M Boughan, DO, Molly M Gallogly, MD PhD, Ehsan Malek, MD, Erin Galloway, RN BSN, Betty K. Hamilton, MD, Matt Kalaycio, MD, Aaron T. Gerds, MD MS, Marcos de Lima, MD

Blood (2019) 134 (Supplement_1): 1948.

https://doi.org/10.1182/blood-2019-125940

Published: 2019

Journal Articles

Meta-Analyses of Clinical Trials Comparing the Progression Free Survival and Adverse Events in Treated Versus Observed Patients with Smoldering and Indolent Multiple Myeloma

Fahrettin Covut, MD, Tariq Zuheir Kewan, MD, Apoorva Anandan, MD, Folashade Otegbeye, MBBChir,MPH, James Driscoll, MD PhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2019) 134 (Supplement_1): 2196.

https://doi.org/10.1182/blood-2019-125954

Published: 2019

Journal Articles

Lymphoma-Specific Venous Thromboembolism Score (LyV-Score): Use of Lymphoma Subtype to Refine Risk Prediction

Shufen Cao, Gouri Dharmavaram, Kirsten M Boughan, DO, Brenda Cooper, MD, Molly M Gallogly, MD PhD, Ehsan Malek, MD, Leland Metheny, III, MD, Folashade Otegbeye, MBBChir,MPH, Benjamin K. Tomlinson, MD, Marcos de Lima, MD, Pingfu Fu, Paolo F Caimi, MD

Blood (2019) 134 (Supplement_1): 4770.

https://doi.org/10.1182/blood-2019-131527

Published: 2019

NARROW

A Phase II Study of Low Dose Melphalan with Thiotepa and Fludarabine As Preparative Regimen for Alternative Donor Transplantation

Autoimmune Outcomes in Patients with Concurrent Autoimmune Disease Receiving CD19 CAR T-Cell Therapy for Lymphoma

Phase 2 Study of CD19 CAR T Cells with a Fully Human Binder for Large B-Cell Lymphoma in Relapse or Progression after a Murine Binder-Bearing CD19 CAR T-Cell Therapy

Machine Learning-Based Time-Series Clustering Identifies Archetypal Trajectories of Hematotoxicity after CAR T-Cell Therapy

Day +3/Day 0 Ferritin Ratio: A Simple Point-of-Care Index Predictive of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome after CD19 CAR T-Cell Therapy

Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World Setting

Phase 2 Study of Anakinra to Prevent CRS and Neurotoxicity after Treatment with Lisocabtagene Maraleucel: Planned Interim Analysis

Multicenter Phase I Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

Circulating Tumor DNA Correlation with Lymphoma Response and Survival Outcomes at Multiple Time Points of Anti - CD19 CAR T Cell Therapy

Final Results of a Phase 1 Study of AntiCD19 CAR-T Cells with TNFRSF19 Transmembrane Domain

Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia

CAR-T Therapy for Lymphoma with Prophylactic Tocilizumab: Decreased Rates of Severe Cytokine Release Syndrome without Excessive Neurologic Toxicity

Final Results of a Dual-Institution Phase I Clinical Trial of Targeted Marrow Irradiation (TMI) Intensification of Reduced-Intensity Fludarabine/Busulfan (Flu/Bu) Conditioning for Allogeneic Hematopoietic Cell Transplantation for Medically Frail Patients with High-Risk Hematological Malignancies

Risk of Secondary Malignancy in CLL Patients Treated with Novel Targeted Agents

15-PGDH Inhibition Mitigates Aplastic Anemia Severity

Phase 1 Study of on Site Manufactured Anti-CD19 CAR-T Cells: Responses in Subjects with Rapidly Progressive Refractory Lymphomas

Filgrastim Administered after Early Assessment Bone Marrow Biopsy during 7+3 Induction Therapy for Acute Myeloid Leukemia Reduces Length of Hospital Stay

Inotuzumab Ozogamicin Post-Transplant for Acute Lymphocytic Leukemia

Meta-Analyses of Clinical Trials Comparing the Progression Free Survival and Adverse Events in Treated Versus Observed Patients with Smoldering and Indolent Multiple Myeloma

Lymphoma-Specific Venous Thromboembolism Score (LyV-Score): Use of Lymphoma Subtype to Refine Risk Prediction

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only